Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 887 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPOCH II Clear all

Conditions: Retinal Disease, Macular Disease
Interventions: Interferon gamma-1b; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autoimmune Inner Ear Disease, Meniere's Disease
Interventions: Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2); Drug
Lead sponsor: Andrea Vambutas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Prostate Cancer
Interventions: Transdermal Estradiol; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 6
States / cities: Freehold, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 2 more

Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: temsirolimus; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 2
States / cities: Rochester, Minnesota • San Antonio, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, M2951; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 42
States / cities: Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more

Conditions: Palmoplantar Keratoderma
Interventions: Tapinarof; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes, Obesity
Interventions: rechargeable TANTALUS II; Device
Lead sponsor: MetaCure (USA), Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Los Angeles, California • San Antonio, Texas

Conditions: Hypertension
Interventions: Metoprolol succinate, Nebivolol, Forearm blood flow, Microneurography, Rhythmic handgrip exercise, Lower body negative pressure, Angiotensin II; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lymphoma
Interventions: filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 80
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 60 more

Conditions: Huntington Disease
Interventions: Tominersen, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 50 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more

Conditions: Endstage Renal Disease
Interventions: EpxDialysis; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions: Ublituximab, Lenalidomide; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Huntsville, Alabama • Bethesda, Maryland

Conditions: Bariatric Surgery
Interventions: Positive Psychology-Motivational Interviewing, Physical Activity Education Control; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Macular Edema
Interventions: Vamikibart, Ranibizumab, Sham Procedure; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Arcadia, California • Torrance, California • Walnut Creek, California + 7 more

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Ipilimumab, Nivolumab, Cryoablation; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obsessive-Compulsive Disorder, OCD
Interventions: Deep Brain Stimulation; Device
Lead sponsor: Andrew Moses Lee, MD, PhD; Other
Eligibility: 22 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Smallpox
Interventions: Brincidofovir; Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Alzheimers Disease
Interventions: CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more

Conditions: Scleroderma, Systemic
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more

Conditions: Melanoma
Interventions: Ipilimumab, Vemurafenib; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 8 more

Conditions: Melanoma
Interventions: 4-peptide and 12-peptide melanoma vaccines; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions: Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs; Procedure · Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Baltimore, Maryland • Lebanon, New Hampshire • Durham, North Carolina + 4 more

Search by objective public record fields.

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer

CCI-779 in Treating Patients With Advanced Solid Tumors

A Phase II Study of M2951 in SLE

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Improving Adherence in Renal Dialysis Patients Through Electronic Interventions

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Gaining Optimism After Weight Loss Surgery (GOALS) II

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Personalized DBS for OCD Guided by Stereoencephalography Mapping

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

A Study of Surgery and Radiotherapy in People With Breast Cancer

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome